Drug
Gemcabene clinical trials
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 1999
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 1999 | 2 |
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2016 | 3 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 2
NeuroBo Pharmaceuticals Inc. (10) · Elif Oral (1) · Emory University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses gemcabene is read from its arms, and is right about nine times in ten.
Testing it · 12
- Gemcabene for the Treatment of Pediatric NAFLDTerminatedPhase 2Emory UniversityNCT03436420Written as Gemcabene
- Study of Gemcabene in Adults With FPLDCompletedPhase 1/2Elif OralNCT03508687Written as 300mg Gemcabene
- Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)CompletedPhase 2NeuroBo Pharmaceuticals Inc.NCT02722408Written as Gemcabene
- A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe HypertriglyceridemiaCompletedPhase 2NeuroBo Pharmaceuticals Inc.NCT02944383Written as Gemcabene
- A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity StatinsCompletedPhase 2NeuroBo Pharmaceuticals Inc.NCT02634151Written as Gemcabene
- Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients on Stable Statin TherapyCompletedPhase 2NeuroBo Pharmaceuticals Inc.NCT02571257Written as Gemcabene
- Effect of Gemcabene on the Pharmacokinetics of Atorvastatin in Healthy VolunteersCompletedPhase 1NeuroBo Pharmaceuticals Inc.NCT02587416Written as Gemcabene 300 mg
- The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic SubjectsCompletedPhase 2NeuroBo Pharmaceuticals Inc.NCT02586168Written as Gemcabene 900 mg
- Efficacy and Safety of Gemcabene in Patients With Low HDL-C and Either Normal or Elevated TriglyceridesCompletedPhase 2NeuroBo Pharmaceuticals Inc.NCT02585869Written as Gemcabene 150 mg
- Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With AtorvastatinCompletedPhase 2NeuroBo Pharmaceuticals Inc.NCT02591836Written as Gemcabene
- Effect of Gemcabene on the Pharmacokinetics of Simvastatin in Healthy VolunteersCompletedPhase 1NeuroBo Pharmaceuticals Inc.NCT02587390Written as Gemcabene 900 mg
- Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy VolunteersCompletedPhase 1NeuroBo Pharmaceuticals Inc.NCT02587364Written as Gemcabene 50 mg
Codes
What other systems call gemcabene · ClinicalTrials.gg INT004051
- MeSH (NLM) C111024gemcabeneOne source NLM
- UNII (FDA) B96UX1DDKSGEMCABENEConfirmed FDA, NLM, Wikidata
- Wikidata Q27095571gemcabeneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C72794GemcabeneOne source FDA
- DrugBank DB05123One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C111024 | gemcabene | One source NLM |
| UNII (FDA) | B96UX1DDKS | GEMCABENE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27095571 | gemcabene | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C72794 | Gemcabene | One source FDA |
| DrugBank | DB05123 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.